Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Tatneft may participate in modernization of Bukhara refinery in Uzbekistan

4/25/23 TATN

TGC-1 reduced electricity generation by 3.44% in the first quarter

4/25/23 TGKA

Kimberly-Clark reported for 3 months of 2023

4/25/23 KMB

Biogen reported for 3 months of 2023

4/25/23 BIIB

Verizon reported for 3 months of 2023

4/25/23 VZ

McDonald's reported for 3 months of 2023

4/25/23 MCD

PulteGroup reported for 3 months of 2023

4/25/23 PHM

3M reported for 3 months of 2023

4/25/23 MMM

General Motors reported for 3 months of 2023

4/25/23 GM

General Electric reported for 3 months of 2023

4/25/23 GE